Showing 651 results
- Media Release /If approved, Xolair self-administration would offer a more flexible option to help select patients manage their treatment needs Filing acceptance is based on the well-established efficacy and…
- Media Release /
- Media Release /Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis¹…
- Media Release /Approximately 3 million people in the US suffer from HFpEF, a life-threatening condition associated with frequent heart failure hospitalizations and emergency room visits, for which no treatment…
- Media Release /
- Media Release /FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis…
- Media Release /FDA granted an indication for active Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) and AOSD, a serious and rare inflammatory disorder with high unmet medical need1,2…
- Media Release /Novartis donates 27,000 units of hand sanitizer to support New York’s response to the COVID-19 public health emergency Donation builds on Novartis efforts in the US for communities impacted by…
- Media Release /Novartis worked with U.S. Food and Drug Administration (FDA) to update BEOVU (brolucizumab-dbll) prescribing information to guide healthcare professionals in their treatment of wet AMD patients1…
- Media Release /
Pagination
- ‹ Previous page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- …
- 66
- › Next page